drugset

drugset / Trial / NCT04601441

Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan

NCT04601441 ↗

Phase 4 Unknown 100 enrolled Kindai University Janssen Pharmaceutical K.K. · collab

NaSingle-groupOpen-labelScreening

Summary

To evaluate changes in genomic alterations for 73 PC driver genes during apalutamide treatment

Timeline

Start: 2020-11-06
Primary completion: 2025-03-31
Completion: 2025-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apalutamide	Small molecule	240 mg	Oral

Indications